**ADUHELM INFORMATION HOTLINE: 1-248-553-6214**
On Wednesday, June 16 MIND distributed the first dose in the county! Read the announcement here.
The FDA announced on Monday, June 7 its approval of Biogen’s Alzheimer’s drug Aduhelm (Aducanumab).
Aduhelm is the first disease modifying therapy approved by the FDA for certain patients with Alzheimer’s Disease (AD).
MIND is working diligently to ensure a seamless process for screening and treatment for their patients, caregivers, and referring providers.
Details are still pending Final FDA notification and payer guidance, however MIND is committed to providing up to date information as soon as possible. Please check back for updates.
Read Biogen’s news release here:
https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-drug
If you are interested in learning more about this treatment, please complete the form below or leave a voicemail message at 1-248-553-6214. We will get back with you as quickly as possible.
